A single amino acid in CaV1.2 controls channel activity and arterial tone in hypertension
CaV1.2 中的单个氨基酸控制高血压中的通道活性和动脉张力
基本信息
- 批准号:10392387
- 负责人:
- 金额:$ 56.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-06-10 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:AcuteAddressAffectAmericanAmino AcidsAngiotensin IIAnimal ModelArteriesBiochemistryBloodBlood PressureBlood VesselsBlood flowCalcineurinCaliberCardiacCardiovascular systemCerebral small vessel diseaseContractile ProteinsCoupledCouplingCyclic AMP-Dependent Protein KinasesDataDevelopmentDiseaseDisputesElectrophysiology (science)FormulationFoundationsGoalsHeartHypertensionImpairmentKnowledgeLeadLinkMeasurementMediatingMembrane PotentialsMethodsMicroscopyMissionModelingMolecularMuscle CellsOpticsOrganOutcomePKC Phosphorylation SitePathologicPerfusionPeripheral Vascular DiseasesPhosphorylationPhosphorylation SitePhosphotransferasesPhysiologicalProteinsPublic HealthRegulationResistanceRisk FactorsRoleSarcolemmaSignal PathwaySignal TransductionSiteStrokeSystemTechniquesTelemetryTestingTherapeuticTissuesUnited States National Institutes of HealthVascular DiseasesWorkarteriolebaseblood pressure regulationconstrictioncostexperimental studyhealth goalshemodynamicsin silicoin vivoinnovationinsightnovelnovel therapeutic interventionpatch clamppressureresponsetherapeutic targettooltranscription factor NF-AT c3treatment strategyvasoconstrictionvirtualvoltage
项目摘要
Ca2+ influx via single or clusters of voltage-gated L-type CaV1.2 channels (LTCC) in arterial myocytes exerts a
major regulatory influence on vascular reactivity and ultimately on blood flow/pressure during physiological and
pathological conditions such as hypertension (HTN). HTN is characterized by enhanced angiotensin II (angII)
signaling. Although substantial evidence suggests that angII acting through the Gq/PKC axis stimulates LTCC
activity, the precise activation mechanism, its impact on vascular reactivity and the link to HTN are unknown.
The overall objective of this proposal is to address this fundamental knowledge gap. Preliminary data herein,
offer a unique window into these queries and uncover an essential role of a single arterial CaV1.2 amino acid as
the culprit for enhanced LTCC function and vascular reactivity during angII signaling and HTN. Our preliminary
data indicate that elevated LTCC activity and vasoconstriction during enhanced angII signaling is the result of
increased PKC-mediated CaV1.2 phosphorylation at S1928, which remarkably is a putative PKA phosphorylation
site with no functional relevance in heart hemodynamics. Increased S1928 phosphorylation (pS1928) underlies a
previously unappreciated redistribution and assembly of CaV1.2 subunits into larger clusters in the sarcolemma,
promoting adjacent LTCCs to gate in unison (i.e. coupled gating). Functional pS1928-mediated LTCC coupling
results in a net amplification of Ca2+ influx leading to activation of prohypertensive signaling pathways,
vasoconstriction and altered blood flow/pressure during enhanced angII signaling and HTN, thus underscoring
the significance of our data. These data led to the formulation of the novel central hypothesis that the
phosphorylation state of a single amino acid - S1928 - in the arterial CaV1.2 subunit, tunes LTCC function and
vascular reactivity during enhanced angII signaling and HTN. Beyond the unforeseen role for S1928 as a
functionally relevant PKC phosphorylation site, an emerging and innovative concept is that pS1928 is a rheostat
of LTCC function and vascular reactivity, and a major risk factor for HTN. Using a multiscale approach that
employs contemporary methods well-established in our group, including innovative microscopy techniques,
sophisticated biochemistry, electrophysiology, telemetry, in silico analysis, and unique animal models, we will
explore the following aims. Aim 1 tests the hypothesis that pS1928 is essential for angII-dependent augmentation
of LTCC activity and vascular reactivity. Aim 2 test the hypothesis that pS1928 facilitates increased LTCC
clustering and coupled gating during enhanced angII signaling. Finally, Aim 3 tests the hypothesis that enhanced
pS1928 is the principal mechanism underlying increased CaV1.2 cluster formation and LTCC activity leading to
vascular dysfunction in HTN. Outcomes will offer new insight linking a single CaV1.2 amino acid with altered
LTCC function and vascular reactivity during enhanced angII signaling and HTN and lay the foundation for novel
therapeutic strategies with single amino acid accuracy to correct LTCC activity and vascular dysfunction.
在动脉肌细胞中,钙离子通过电压门控的L型钙离子通道(LTCC)单通道或成簇内流
对血管反应性的主要调节影响,并最终影响生理和
病理情况,如高血压(HTN)。HTN的特点是血管紧张素II(AngII)增强
发信号。尽管大量证据表明,通过GQ/PKC轴作用的AngII刺激LTCC
活性、确切的激活机制、对血管反应性的影响以及与HTN的联系尚不清楚。
这项建议的总体目标是解决这一根本的知识差距。这里有初步数据,
为这些查询提供了一个独特的窗口,并揭示了单个动脉CaV1.2氨基酸作为
AngiI信号和HTN过程中LTCC功能和血管反应性增强的罪魁祸首。我们的预赛
数据表明,在增强的AngII信号转导过程中,LTCC活性和血管收缩增加是以下因素的结果
在S1928,PKC介导的CaV1.2磷酸化增加,这是一种假定的PKA磷酸化
与心脏血流动力学无功能相关性的部位。S1928磷酸化增强(PS1928)是
以前不受欢迎的CaV1.2亚基在肌膜中重新分布和组装成更大的簇,
将相邻的LTCC同步提升到栅极(即耦合栅极)。功能性pS1928介导的LTCC偶联
结果导致钙离子内流的净放大导致高血压信号通路的激活,
血管收缩和血流/压力改变在增强的AngII信号和HTN过程中,因此强调
我们数据的重要性。这些数据导致了新的中心假设的形成,即
动脉CaV1.2亚基中单个氨基酸S1928的磷酸化状态调节LTCC功能和
血管反应性在血管紧张素Ⅱ信号和HTN增强。超越了S1928作为一个
与功能相关的PKC磷酸化位点,一个新兴和创新的概念是pS1928是一个变阻器
LTCC功能和血管反应性,是HTN的主要危险因素。使用多尺度方法,
使用在我们团队中成熟的现代方法,包括创新的显微技术,
先进的生物化学、电生理学、遥测、电子分析和独特的动物模型,我们将
探索以下目标。目的1验证pS1928对血管紧张素转换酶依赖的增强必不可少的假设
LTCC活性和血管反应性。目的2检验pS1928促进LTCC增加的假设
增强的Angii信令期间的集群和耦合门控。最后,Aim 3测试了增强的假设
PS1928是导致CaV1.2团簇形成增加和LTCC活动导致
HTN中的血管功能障碍。结果将提供新的见解,将单个CaV1.2氨基酸与改变的
在AngiI信号和HTN增强过程中LTCC的功能和血管反应性,为新的
具有单一氨基酸准确性的治疗策略,以纠正LTCC活动和血管功能障碍。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Manuel F Navedo其他文献
Manuel F Navedo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Manuel F Navedo', 18)}}的其他基金
Regulation of a cardiac b1AR/SERCA2 complex in heart failure
心力衰竭中心脏 b1AR/SERCA2 复合物的调节
- 批准号:
10641923 - 财政年份:2022
- 资助金额:
$ 56.47万 - 项目类别:
Regulation of a cardiac b1AR/SERCA2 complex in heart failure
心力衰竭中心脏 b1AR/SERCA2 复合物的调节
- 批准号:
10539066 - 财政年份:2022
- 资助金额:
$ 56.47万 - 项目类别:
cAMP signaling in vascular smooth muscle in health and disease
健康和疾病状态下血管平滑肌中的 cAMP 信号传导
- 批准号:
10370716 - 财政年份:2021
- 资助金额:
$ 56.47万 - 项目类别:
cAMP signaling in vascular smooth muscle in health and disease
健康和疾病状态下血管平滑肌中的 cAMP 信号传导
- 批准号:
10532163 - 财政年份:2021
- 资助金额:
$ 56.47万 - 项目类别:
Cerebral Vascular Smooth Muscle Dysfunction in Alzheimer's Disease
阿尔茨海默氏病的脑血管平滑肌功能障碍
- 批准号:
10488479 - 财政年份:2019
- 资助金额:
$ 56.47万 - 项目类别:
Coupling of Vascular Cav1.2 Channels In Health & Disease
健康中血管 Cav1.2 通道的耦合
- 批准号:
8960054 - 财政年份:2015
- 资助金额:
$ 56.47万 - 项目类别:
Coupling of vascular CaV1.2 channels in health and disease
血管 CaV1.2 通道在健康和疾病中的耦合
- 批准号:
10306953 - 财政年份:2015
- 资助金额:
$ 56.47万 - 项目类别:
Coupling of vascular CaV1.2 channels in health and disease
血管 CaV1.2 通道在健康和疾病中的耦合
- 批准号:
10613545 - 财政年份:2015
- 资助金额:
$ 56.47万 - 项目类别:
Coupling of vascular CaV1.2 channels in health and disease
血管 CaV1.2 通道在健康和疾病中的耦合
- 批准号:
10451644 - 财政年份:2015
- 资助金额:
$ 56.47万 - 项目类别:
Calcium sparklets-induced vascular dysfunction during diabetes
糖尿病期间钙火花诱导的血管功能障碍
- 批准号:
7982925 - 财政年份:2010
- 资助金额:
$ 56.47万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 56.47万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 56.47万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 56.47万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 56.47万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 56.47万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 56.47万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 56.47万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 56.47万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 56.47万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 56.47万 - 项目类别:
Research Grant